NYSE Euronext (NYX) today announced trading volumes for its
global derivatives and cash equities exchanges for March 20131.
Global derivatives average daily volume (“ADV”) of 8.1 million
contracts in March 2013 was in-line with March 2012, but decreased
7.8% from February 2013. European derivatives products ADV in March
2013 of 4.3 million contracts increased 8.9% compared to March
2012, but decreased 2.8% from February 2013 levels. NYSE Liffe U.S.
rebounded 62.7% versus the prior month. Trading volumes in European
and U.S. cash equities declined both year-over-year and
month-over-month.
Highlights
- NYSE Euronext global derivatives ADV in
March 2013 of 8.1 million contracts was in line with March 2012,
and decreased 7.8% from February 2013 levels.
- NYSE Euronext European derivatives
products ADV in March 2013 of 4.3 million contracts increased 8.9%
compared to March 2012, but decreased 2.8% from February 2013
levels. Excluding Bclear, NYSE Liffe's trade administration and
clearing service for OTC products, European derivatives products
ADV increased 21.4% compared to March 2012, but decreased 6.7% from
February 2013.
- NYSE Euronext U.S. equity options (NYSE
Arca and NYSE Amex Options) ADV of 3.8 million contracts in March
2013 decreased 8.6% compared to March 2012 levels, and decreased by
13.7% from February 2013 levels. NYSE Euronext’s U.S. options
exchanges accounted for 26.9% of total U.S. consolidated equity
options trading in March 2013, up from 26.0% in March 2012, but
down from 28.2% in February 2013.
- NYSE Liffe U.S. ADV of approximately
78,100 contracts decreased from 104,900 contracts in March 2012,
but increased from 48,000 contracts in February 2013.
- NYSE Euronext European cash products
ADV of 1.4 million transactions in March 2013 decreased 14.4%
compared to March 2012 and decreased 4.6% compared to February
2013.
- NYSE Euronext U.S. cash products (NYSE,
NYSE Arca and NYSE-MKT) handled ADV of 1.5 billion shares in March
2013 decreased 13.8% compared to March 2012 and decreased 2.7%
compared to February 2013. NYSE Euronext’s Tape A matched market
share in March 2013 was 31.1%, down slightly from 31.3% in March
2012, but up from 29.4% in February 2013.
- The preliminary average net revenue per
transaction type (as defined below) for each of the primary trading
venues in the first quarter of 2013 is included below:
Preliminary
Trading Venue 1Q12
4Q12 1Q13 European Derivatives (ex.
Bclear)1 $0.659 $0.673 $0.62
U.S. Derivatives2 $0.148 $0.144
$0.15 European Cash3 $0.573
$0.583 $0.61 U.S. Cash4
$0.043 $0.040
$0.04 1 Average net revenue per contract, excluding Bclear.
2 Average net revenue per contract. Excludes NYSE Liffe U.S.
trading volume. 3 Average net revenue per transaction. 4 Average
net revenue per 100 shares handled.
Other Metrics
- There were no large one-time managed
services sales in the first quarter of 2013 for the Information
Services and Technology Solutions segment, as were recorded in the
fourth quarter with the ATG sale and in the first quarter of 2012
with the technology sale to the Warsaw Stock Exchange. However, our
market data initiatives are on track to start building in April
2013.
- In the first quarter, we incurred an
incremental $3.5 million pre-tax charge related to cash-settled
restricted stock unit awards, as a result of the increase in our
stock price.
- The average EUR/USD exchange rate for
the first quarter of 2013 of $1.32 represented an increase of 1.7%
from the fourth quarter of 2012 and an increase of 0.7% compared to
the first quarter of 2012. The average GBP/USD exchange rate for
the first quarter of 2013 of $1.55 represented a decrease of 3.4%
from the fourth quarter of 2012 and a decrease of 1.2% compared to
the first quarter of 2012.
Please click here for the Monthly Transaction Activity Data
Table.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial
markets and provider of innovative trading technologies. The
company's exchanges in Europe and the United States trade equities,
futures, options, fixed-income and exchange-traded products. With
approximately 8,000 listed issues (excluding European Structured
Products), NYSE Euronext's equities markets - the New York Stock
Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca -
represent one-third of the world’s equities trading, the most
liquidity of any global exchange group. NYSE Euronext also operates
NYSE Liffe, one of the leading European derivatives businesses and
the world's second-largest derivatives business by value of
trading. The company offers comprehensive commercial technology,
connectivity and market data products and services through NYSE
Technologies. NYSE Euronext is in the S&P 500 index. For more
information, please visit: http://www.nyx.com.
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING
STATEMENTS
This communication contains “forward-looking statements” made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases, you can identify
forward-looking statements by words such as “may,” “hope,” “will,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “potential,” “continue,” “could,” “future”
or the negative of those terms or other words of similar meaning.
You should carefully read forward-looking statements, including
statements that contain these words, because they discuss our
future expectations or state other “forward-looking” information.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties which change over time. ICE and NYSE
Euronext caution readers that any forward-looking statement is not
a guarantee of future performance and that actual results could
differ materially from those contained in the forward-looking
statement.
Forward-looking statements include, but are not limited to,
statements about the benefits of the proposed merger involving ICE
and NYSE Euronext, including future financial results, ICE’s and
NYSE Euronext’s plans, objectives, expectations and intentions, the
expected timing of completion of the transaction and other
statements that are not historical facts. Important factors that
could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in ICE’s
and NYSE Euronext’s filings with the U.S. Securities and Exchange
Commission (the “SEC”). These risks and uncertainties include,
without limitation, the following: the inability to close the
merger in a timely manner; the inability to complete the merger due
to the failure of NYSE Euronext stockholders to adopt the merger
agreement or the failure of ICE stockholders to approve the
issuance of ICE common stock in connection with the merger; the
failure to satisfy other conditions to completion of the merger,
including receipt of required regulatory and other approvals; the
failure of the proposed transaction to close for any other reason;
the possibility that any of the anticipated benefits of the
proposed transaction will not be realized; the risk that
integration of NYSE Euronext’s operations with those of ICE will be
materially delayed or will be more costly or difficult than
expected; the challenges of integrating and retaining key
employees; the effect of the announcement of the transaction on
ICE’s, NYSE Euronext’s or the combined company’s respective
business relationships, operating results and business generally;
the possibility that the anticipated synergies and cost savings of
the merger will not be realized, or will not be realized within the
expected time period; the possibility that the merger may be more
expensive to complete than anticipated, including as a result of
unexpected factors or events; diversion of management’s attention
from ongoing business operations and opportunities; general
competitive, economic, political and market conditions and
fluctuations; actions taken or conditions imposed by the United
States and foreign governments or regulatory authorities; and
adverse outcomes of pending or threatened litigation or government
investigations. In addition, you should carefully consider the
risks and uncertainties and other factors that may affect future
results of the combined company, as are described in the section
entitled “Risk Factors” in the joint proxy statement/prospectus
filed by ICE with the SEC, and as described in ICE’s and NYSE
Euronext’s respective filings with the SEC that are available on
the SEC’s web site located at www.sec.gov, including the sections
entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year
ended December 31, 2012, as filed with the SEC on February 6, 2013,
and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year
ended December 31, 2012, as filed with the SEC on February 26,
2014. You should not place undue reliance on forward-looking
statements, which speak only as of the date of this written
communication. Except for any obligations to disclose material
information under the Federal securities laws, neither ICE nor NYSE
Euronext undertakes any obligation to publicly update any
forward-looking statements to reflect events or circumstances after
the date of this written communication.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
WHERE TO FIND IT
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval. In connection with the proposed transaction,
ICE has filed with the SEC a registration statement on Form S-4,
which includes a joint proxy statement/prospectus with respect to
the proposed acquisition of NYSE Euronext. The final joint proxy
statement/prospectus will be delivered to the stockholders of ICE
and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND
NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY
AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH
THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY
STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO
THOSE DOCUMENTS, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION
REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION.
Investors and security holders may obtain a free copy of the joint
proxy statement/prospectus, as well as other filings containing
information about ICE and NYSE Euronext, without charge, at the
SEC’s website at http://www.sec.gov. Investors may also obtain
these documents, without charge, from ICE’s website at
http://www.theice.com and from NYSE Euronext’s website at
http://www.nyx.com
PARTICIPANTS IN THE MERGER SOLICITATION
ICE, NYSE Euronext and their respective directors, executive
officers and other members of management and employees may be
deemed to be participants in the solicitation of proxies in respect
of the transactions contemplated by the Merger Agreement.
You can find information about ICE and ICE’s directors and
executive officers in ICE’s Annual Report on Form 10-K for the year
ended December 31, 2012, as filed with the SEC on February 6, 2013,
and ICE’s proxy statement for its 2013 annual meeting of
stockholders, as filed with the SEC on March 28, 2012.
You can find information about NYSE Euronext and NYSE Euronext’s
directors and executive officers in NYSE Euronext’s Annual Report
on Form 10-K for the year ended December 31, 2012, as filed with
the SEC on February 26, 2013, and NYSE Euronext’s proxy statement
for its 2013 annual meeting of stockholders, filed with the SEC on
March 22, 2013.
Additional information about the interests of potential
participants will be included in the joint proxy
statement/prospectuses, when it becomes available, and the other
relevant documents filed by ICE and NYSE Euronext with the SEC.
1 All NYSE Euronext derivatives transactions count buy and sell
orders together as a single transaction. NYSE Euronext European
equities transactions count each buy and sell order as separate
transactions, NYSE Euronext U.S. equities transactions count buy
and sell orders together as a single transaction.
NYSE
Euronext
Monthly Volume
Summary
Average Daily Volume Total Volume
Average Daily Volume Total
Volume (Unaudited; contracts in thousands)
Mar-13 Mar-12 %
Chg Mar-13
Mar-12 % Chg YTD
2013
% Chg vs.YTD
2012
YTD 2013
% Chg vs.YTD
2012
Number of Trading Days - European Cash 20 22 20 22 62 62
Number of Trading Days - European Derivatives 20 22 20 22 62 62
Number of Trading Days - U.S. Markets 20 22 20 22 60 60
European Derivatives Products 4,260 3,913
8.9% 85,207 86,080 -1.0% 4,515
35.5% 279,936 29.2% of which Bclear 864 1,115
-22.5% 17,287 24,535 -29.5% 883 31.3% 54,749 25.2%
Total
Fixed Income Products 2,456 1,876 30.9%
49,115 41,272 19.0% 2,749 54.9%
170,433 47.8% Short Term Interest Rate
Products 2,305 1,735 32.8% 46,095 38,170 20.8% 2,560 57.8% 158,710
50.5% Medium and Long Term Interest Rate Products 1 151 141 7.1%
3,020 3,102 -2.6% 189 24.3% 11,723 18.5%
Total Equity
Products 2 1,715 1,955 -12.2%
34,304 43,002 -20.2% 1,674 13.4%
103,802 8.2% Individual Equity Products 1,090
1,393 -21.7% 21,807 30,655 -28.9% 1,132 11.1% 70,179 5.9% Futures
600 902 -33.5% 11,995 19,840 -39.5% 660 29.4% 40,948 23.4% Options
491 492 -0.2% 9,812 10,814 -9.3% 471 -7.3% 29,231 -11.6% Equity
Index Products 625 561 11.3% 12,497 12,347 1.2% 542 18.6% 33,623
13.1% of which Bclear 864 1,115 -22.6% 17,271 24,535 -29.6%
881 31.0% 54,639 24.9% Individual Equity Products 726 1,007 -27.9%
14,516 22,144 -34.4% 758 26.4% 47,008 20.5% Futures 600 902 -33.5%
11,994 19,837 -39.5% 649 29.3% 40,267 23.3%
Options
126 105 20.2% 2,522 2,307 9.3% 109 11.5% 6,742 6.4% Equity Index
Products 138 109 26.8% 2,756 2,391 15.2% 123 69.1% 7,630 61.3%
Commodity Products 89 82 8.9%
1,788 1,806 -1.0% 92 12.9%
5,701 7.7% U.S. Derivatives Products
Equity Options 3 NYSE Euronext Options
Contracts 3,750 4,105 -8.6% 75,007 90,300 -16.9% 4,231 2.5% 253,843
-0.8% Total Consolidated Options Contracts 13,952 15,811 -11.8%
279,047 347,851 -19.8% 14,981 -5.7% 898,885 -8.7% NYSE Group
Share of Total 26.9% 26.0% 26.9% 26.0% 28.2% 2.2% 28.2% 2.2%
NYSE Liffe U.S. Futures and Futures Options Volume*
78.1 104.9 -25.6% 1,561 2,308 -32.4% 58.7 -39.0% 3,641.1 -40.9%
European Cash Products (trades in thousands)
1,391 1,625 -14.4% 27,820 35,743
-22.2% 1,378 -13.0% 85,419
-17.0% Equities 1,340 1,571 -14.7% 26,808 34,565
-22.4% 1,326 -13.3% 82,199 -17.3% Exchange-Traded Funds 14 14 -6.4%
270 318 -14.9% 14 -5.6% 848 -9.9% Structured Products 32 34 -6.2%
641 752 -14.8% 33 -5.3% 2,019 -9.7% Bonds 5 5 1.4% 101 109 -7.9% 6
19.1% 353 13.6%
U.S. Cash Products (shares in
millions) 5 1,520 1,763 -13.8%
30,407 38,793 -21.6% 1,545
-13.3% 92,721 -16.1% NYSE Listed
(Tape A) Issues 4 Handled Volume 5 1,116 1,273
-12.4% 22,319 28,015 -20.3% 1,120 -12.1% 67,207 -15.0% Matched
Volume 6 1,077 1,204 -10.6% 21,531 26,482 -18.7% 1,077 -10.4%
64,603 -13.3% Total NYSE Listed Consolidated Volume 3,467 3,841
-9.8% 69,330 84,503 -18.0% 3,585 -8.8% 215,111 -11.8%
Share of Total Consolidated Volume Handled Volume 5 32.2%
33.2% -1.0% 32.2% 33.2% -1.0% 31.2% -1.2% 31.2% -1.2% Matched
Volume 6 31.1% 31.3% -0.2% 31.1% 31.3% -0.2% 30.0% -0.5% 30.0%
-0.5%
NYSE Arca, MKT and Regional (Tape B) Listed
Issues Handled Volume 5 226 266 -14.9% 4,522 5,846
-22.7% 224 -15.4% 13,466 -18.1% Matched Volume 6 209 237 -11.6%
4,185 5,210 -19.7% 207 -12.4% 12,435 -15.2% Total NYSE Arca &
MKT Listed Consolidated Volume 1,001 1,128 -11.3% 20,020 24,818
-19.3% 994 -11.4% 59,667 -14.3%
Share of Total
Consolidated Volume Handled Volume 5 22.6% 23.6% -1.0% 22.6%
23.6% -1.0% 22.6% -1.0% 22.6% -1.0% Matched Volume 6 20.9% 21.0%
-0.1% 20.9% 21.0% -0.1% 20.8% -0.2% 20.8% -0.2%
Nasdaq
Listed (Tape C) Issues Handled Volume 5 178 224 -20.5%
3,566 4,932 -27.7% 201 -17.5% 12,048 -20.2% Matched Volume 6 160
189 -15.3% 3,204 4,162 -23.0% 179 -13.0% 10,758 -15.8% Total Nasdaq
Listed Consolidated Volume 1,700 1,680 1.2% 34,005 36,951 -8.0%
1,822 1.5% 109,316 -1.8%
Share of Total Consolidated
Volume Handled Volume 5 10.5% 13.3% -2.8% 10.5% 13.3% -2.8%
11.0% -2.5% 11.0% -2.5% Matched Volume 6 9.4% 11.3% -1.9% 9.4%
11.3% -1.9% 9.8% -1.7% 9.8% -1.7%
Exchange-Traded
Products 5,7 Handled Volume 5 210 250 -16.1%
4,192 5,499 -23.8% 212 -14.6% 12,733 -17.4% Matched Volume 6 194
222 -12.8% 3,879 4,890 -20.7% 196 -11.4% 11,761 -14.3% Total ETF
Consolidated Volume 955 1,092 -12.5% 19,108 24,034 -20.5% 959
-11.5% 57,554 -14.4%
Share of Total Consolidated
Volume Handled Volume 5 21.9% 22.9% -1.0% 21.9% 22.9% -1.0%
22.1% -0.8% 22.1% -0.8% Matched Volume 6 20.3% 20.3% 0.0% 20.3%
20.3% 0.0% 20.4% 0.0% 20.4% 0.0% 1 Data includes currency
products.
2
Includes all trading activities for Bclear, NYSE Liffe's clearing
service for wholesale derivatives. 3 Includes trading in U.S.
equity options contracts, not equity-index options. 4 Includes all
volume executed in NYSE Group crossing sessions. 5
Represents the total number of shares of
equity securities and ETFs internally matched on the NYSE Group's
exchanges or routed to andexecuted at an external market center.
NYSE Arca routing includes odd-lots.
6 Represents the total number of shares of equity securities and
ETFs executed on the NYSE Group's exchanges. 7 Data included in
previously identified categories. * ADVs calculated with the
appropriate number of NYSE Liffe U.S. trading days. Source: NYSE
Euronext, Options Clearing Corporation and Consolidated Tape as
reported for equity securities. All trading activity is
single-counted, except European cash trading which is double
counted to include both buys and sells.
Please follow us at:Exchanges BlogFacebookLinkedInTwitter
Grafico Azioni NYSE Group (NYSE:NYX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni NYSE Group (NYSE:NYX)
Storico
Da Lug 2023 a Lug 2024